RYTM icon

Rhythm Pharmaceuticals

62.49 USD
+0.08
0.13%
Updated May 22, 9:34 AM EDT
1 day
0.13%
5 days
4.29%
1 month
5.50%
3 months
14.32%
6 months
4.25%
Year to date
4.03%
1 year
65.14%
5 years
210.59%
10 years
154.33%
 

About: Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Employees: 283

0
Funds holding %
of 7,245 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

521% more call options, than puts

Call options by funds: $21.5M | Put options by funds: $3.46M

130% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 20

23% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 69

12% more funds holding

Funds holding: 202 [Q4 2024] → 227 (+25) [Q1 2025]

3.33% less ownership

Funds ownership: 105.6% [Q4 2024] → 102.27% (-3.33%) [Q1 2025]

6% less capital invested

Capital invested by funds: $3.63B [Q4 2024] → $3.43B (-$207M) [Q1 2025]

36% less funds holding in top 10

Funds holding in top 10: 11 [Q4 2024] → 7 (-4) [Q1 2025]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$68
9%
upside
Avg. target
$79
26%
upside
High target
$92
47%
upside

7 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Joseph Stringer
15%upside
$72
Buy
Maintained
7 May 2025
B of A Securities
Tazeen Ahmad
9%upside
$68
Buy
Maintained
10 Apr 2025
HC Wainwright & Co.
Raghuram Selvaraju
28%upside
$80
Buy
Reiterated
8 Apr 2025
Canaccord Genuity
Whitney Ijem
47%upside
$92
Buy
Maintained
8 Apr 2025
Wells Fargo
Derek Archila
46%upside
$91
Overweight
Maintained
7 Apr 2025

Financial journalist opinion

Based on 8 articles about RYTM published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE); 32 nd annual European Congress on Obesity (ECO); and the 2025 annual meeting of the Pediatric Endocrine Society (PES 2025) -- BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the presentation of new, real-world data at two European congresses that show consistent improvements in body mass index (BMI), BMI-z, and hunger scores in a total of 35 patients with acquired or congenital hypothalamic obesity who were treated with setmelanotide for up to nine months. Physicians from Sorbonne University in Paris delivered two oral presentations with data from patients in the early-access programs in France.
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
Neutral
Seeking Alpha
2 weeks ago
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
2 weeks ago
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $2.35 per share a year ago.
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
2 weeks ago
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
-- First quarter 2025 net product revenue from global sales of IMCIVREE ®  (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity --
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
Neutral
GlobeNewsWire
2 weeks ago
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 12:20 a.m.
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Negative
Zacks Investment Research
3 weeks ago
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
Positive
Zacks Investment Research
3 weeks ago
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?
Neutral
GlobeNewsWire
4 weeks ago
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update.
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
Positive
Seeking Alpha
1 month ago
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Rhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmelanotide to the U.S. and EU, for the treatment of patients with acquired hypothalamic obesity, expected in Q3 of 2025. Company pushing forward with oral MC4R-specific agonist to treat patients with acquired hypothalamic obesity known as bivamelagon;
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Positive
Zacks Investment Research
1 month ago
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
Charts implemented using Lightweight Charts™